1
|
Zore M, Gilbert-Girard S, Reigada I, Patel JZ, Savijoki K, Fallarero A, Yli-Kauhaluoma J. Synthesis and Biological Evaluation of Fingolimod Derivatives as Antibacterial Agents. ACS OMEGA 2021; 6:18465-18486. [PMID: 34308078 PMCID: PMC8296573 DOI: 10.1021/acsomega.1c02591] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 06/29/2021] [Indexed: 05/11/2023]
Abstract
We recently identified fingolimod as a potent antibiofilm compound by screening FDA-approved drugs. To study if the antibacterial activity of fingolimod could be further improved and to explore in-depth structure-activity relationships, we synthesized 28 novel fingolimod derivatives and evaluated their efficacy against Staphylococcus aureus grown in planktonic/single cell and biofilms. The most effective derivatives were tested on preformed S. aureus biofilms and against Gram-negative bacteria Acinetobacter baumannii and Pseudomonas aeruginosa, using fingolimod as the reference compound. Seven derivatives were more effective against S. aureus, while five other derivatives showed improved activity against P. aeruginosa and/or A. baumannii, with no apparent change in cytotoxicity on human cells. The most interesting derivatives, compounds 43 and 55, displayed a broader spectrum of antibacterial activity, possibly exerted by the change of the para-hydrocarbon chain to a meta position for 43 and by an additional hydroxyl group for 55.
Collapse
Affiliation(s)
- Matej Zore
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Shella Gilbert-Girard
- Drug
Research Program, Division of Pharmaceutical Biosciences, Faculty
of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Inés Reigada
- Drug
Research Program, Division of Pharmaceutical Biosciences, Faculty
of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Jayendra Z. Patel
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Kirsi Savijoki
- Drug
Research Program, Division of Pharmaceutical Biosciences, Faculty
of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Adyary Fallarero
- Drug
Research Program, Division of Pharmaceutical Biosciences, Faculty
of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| | - Jari Yli-Kauhaluoma
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00014 Helsinki, Finland
| |
Collapse
|
2
|
Vinigari K, Jonnada K, Mohammed N, Kotu GM. An alternative efficient approach for the synthesis of Fingolimod hydrochloride. SYNTHETIC COMMUN 2019. [DOI: 10.1080/00397911.2018.1536788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Krishna Vinigari
- Research & Development Centre, IPDO-API, Innovation Plaza, Dr. Reddy’s Laboratories Limited , Hyderabad , Telangana , India
- Department of Chemistry, Palamuru University , Mahbubnagar , Telangana , India
| | - Krishna Jonnada
- Research & Development Centre, IPDO-API, Innovation Plaza, Dr. Reddy’s Laboratories Limited , Hyderabad , Telangana , India
| | - Noorjahan Mohammed
- Department of Chemistry, Palamuru University , Mahbubnagar , Telangana , India
| | | |
Collapse
|
3
|
Yan N, Chen K, Bai X, Bi L, Yao L. A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis. Chem Cent J 2015; 9:5. [PMID: 25657817 PMCID: PMC4317520 DOI: 10.1186/s13065-015-0081-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 01/13/2015] [Indexed: 11/24/2022] Open
Abstract
A concise route for the synthesis of Fingolimod is reported. Starting
from n-octylbenzene and 3-nitropropionic acid, a sequence of reactions consisting of
Friedel-Crafts acylation, reduction, and double Henry reaction, followed by
hydrogenation were applied to prepare Fingolimod with a yield of 31%, and an overall
atom economy of 82.7%. Starting from 3-nitropropanyl chloride,
Fingolimod was obtained in 4 steps with an overall yield of
31%. ![]()
Collapse
|
4
|
Maluenda I, Navarro O. Recent developments in the Suzuki-Miyaura reaction: 2010-2014. Molecules 2015; 20:7528-57. [PMID: 25919276 PMCID: PMC6272665 DOI: 10.3390/molecules20057528] [Citation(s) in RCA: 249] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Revised: 04/10/2015] [Accepted: 04/13/2015] [Indexed: 12/21/2022] Open
Abstract
The Suzuki-Miyaura reaction (SMR), involving the coupling of an organoboron reagent and an organic halide or pseudo-halide in the presence of a palladium or nickel catalyst and a base, has arguably become one of most utilized tools for the construction of a C-C bond. This review intends to be general account of all types of catalytic systems, new coupling partners and applications, including the literature between September 2010 and December 2014.
Collapse
Affiliation(s)
- Irene Maluenda
- Department of Chemistry, University of Sussex, Brighton BN1 9QJ, UK
| | - Oscar Navarro
- Department of Chemistry, University of Sussex, Brighton BN1 9QJ, UK.
| |
Collapse
|
5
|
Hikawa H, Hamada M, Uchida Y, Kikkawa S, Yokoyama Y, Azumaya I. Enantioselective desymmetrization of FTY720. Chem Pharm Bull (Tokyo) 2014; 62:1041-4. [PMID: 25273063 DOI: 10.1248/cpb.c14-00462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A method for enantioselective desymmetrization of N-Ac and N-Boc-FTY720 by nonenzymatic asymmetric acylation was developed. Effective enantioselective monobenzoylation using benzoyl chloride in the presence of the tetraphenylbisoxazoline (L2)-CuCl2 complex gave the desired products 3a and 3b in 52-62% yield with 64% ee.
Collapse
|
6
|
Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014; 57:5509-24. [PMID: 24471412 DOI: 10.1021/jm4011687] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Sphingosine kinase (SphK) is an oncogenic lipid kinase that regulates the sphingolipid metabolic pathway that has been shown to play a role in numerous hyperproliferative/inflammatory diseases. The SphK isoforms (SphK1 and SphK2) catalyze the conversion of the proapoptotic substrate d-erythrosphingosine to the promitogenic/migratory product sphingosine 1-phosphate (S1P). Accumulation of S1P has been linked to the development/progression of cancer and various other diseases including, but not limited to, asthma, inflammatory bowel disease, rheumatoid arthritis, and diabetic nephropathy. SphK therefore represents a potential new target for developing novel therapeutics for cancer and other diseases. This finding has stimulated the development and evaluation of numerous SphK inhibitors over the past decade or so. In this review, we highlight the recent advancement in the field of SphK inhibitors including SphK1 and SphK2 specific inhibitors. Both sphingolipid based and nolipidic small molecule inhibitors and their importance in treatment of cancer and other diseases are discussed.
Collapse
Affiliation(s)
- Daniel Plano
- Department of Pharmacology, Penn State Hershey Cancer Institute, CH72, Penn State College of Medicine , 500 University Drive, Hershey, Pennsylvania 17033, United States
| | | | | |
Collapse
|